• Zaynich commercialization timeline: Wockhardt plans to launch Zaynich in the US market early next year, with the India launch expected around the same time or one to two months prior.
• Raw material costs: Following the easing of geopolitical conflicts, the company noted a 5% to 7% reduction in material costs in India, with expectations of decreases reaching 10% over the next month.
• Biologics growth outlook: Driven by diabetes capacity expansion and insulin products such as Glargine and Aspart, the company expects compounded growth exceeding 20% within one to two years across India and emerging markets.
• FY28 financial trajectory: While FY27 will involve early launch and establishment costs to build out the US organization, significant revenue improvement is projected for FY28 from Zaynich in India and the US.